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Abstract
We sought to identify susceptibility genes for high-grade serous ovarian cancer (HGSOC) by 
performing a transcriptome-wide association study (TWAS) of gene expression and splice junction 
usage in HGSOC-relevant tissue types (N = 2,169) and the largest GWAS available for HGSOC 
(N = 13,037 cases/40,941 controls). We identified 25 TWAS significant genes, 7 at the junction 
level only, including LRRC46 at 19q21.32, (P = 1 × 10−9), CHMP4C at 8q21 (P = 2 × 10−11), and 
a PRC1 junction at 15q26 (P = 7 × 10−9). In vitro assays for CHMP4C showed the associated 
variant induces allele specific exon inclusion (P = 0.0024). Functional screens in HGSOC cell 
lines found evidence of essentiality for three of the novel genes we identified: HAUS6, KANSL1 
and PRC1, with the latter comparable to CMYC. Our study implicated at least one target gene for 
6/13 distinct GWAS regions, identifying 23 novel candidate susceptibility genes for HGSOC.
Keywords
epithelial ovarian cancer (EOC); high-grade serous ovarian cancer (HGSOC); RNA-sequencing 
(RNA-seq); expression quantitative trait locus analysis (eQTL); splice site quantitative trait locus 
analysis (spQTL); ovarian surface epithelial cells (OSECs); fallopian tube secretory epithelial cells 
(FTSECs); Genome wide association studies (GWAS); The Cancer Genome Atlas (TCGA); 
Transcriptome-wide association study (TWAS); splice-Transcriptome-wide association study 
(spTWAS)
INTRODUCTION
Invasive epithelial ovarian cancer (EOC) is a heterogeneous disease with a major heritable 
component 1. There are several histological subtypes of invasive EOC, each associated with 
different genetic and epidemiological risk factors, clinical features and likely cells of origin. 
High grade serous ovarian cancer (HGSOC) is the most common histotype, representing 
about two-thirds of cases. Highly penetrant germline mutations in the homology directed 
repair genes including BRCA1 and BRCA2 are the most significant genetic risk factors for 
HGSOC, but only account for about 10% of cases 1. A major fraction of the remaining EOC 
risk is due to common, low penetrance risk alleles, and over the last few years, genome-wide 
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association studies (GWASs) have identified 39 different regions of the genome associated 
with EOC risk, mainly in European populations 2–13.
Typically, SNPs associated with disease risk are located in the non-protein coding genome 
suggesting they function by altering the activity of non-coding biofeatures (e.g. DNA 
enhancers, non-coding RNAs) that regulate gene expression. Expression quantitative trait 
locus (eQTL) analysis can be used to identify associations between risk genotypes and gene 
expression and several studies have successfully used this approach to identify putative 
susceptibility genes at GWAS risk loci 2,3,14,15, including in epithelial ovarian cancer 
2,3,6–9,14,15
. Recently, transcriptome-wide association studies (TWASs) have been proposed 
as a principled approach to integrate eQTL analyses with GWAS to identify genes whose 
genetically regulated expression is associated to disease risk 16–20. For a given gene, TWASs 
use eQTL data to ‘impute’ the total expression across a large cohort of genotyped 
individuals followed by a test of association with disease risk. TWAS may additionally 
increase power versus single SNP association testing either by reducing the multiple testing 
burden or aggregating multiple expression-altering variants into a single test. However, 
TWASs may also identify significant associations due to pleiotropy between the expression-
altering and risk-altering variants or variants they tag 16,21. A TWAS is therefore a first step 
to prioritize putative target genes, with experimental validation needed to establish causality.
In the current study we established the most comprehensive genome-wide genotype-gene 
expression datasets available, with >2,000 eQTL samples in primary HGSOCs, EOC 
precursor tissues (ovarian and fallopian epithelial cells) and other hormonal-related cancers 
(breast and prostate cancer), to perform multi-tissue TWASs in the largest ovarian cancer 
GWAS available (N > 50,000). In addition to performing traditional TWAS that test for 
association at total abundance levels, we extend the TWAS methodology to integrate splice-
QTLs by also testing exon junction levels for association to EOC (‘spTWAS’). We identify 
25 genes whose expression is significantly associated to EOC risk at genome-wide 
significance, 7 of which are only significant in the spTWAS, thus underscoring the utility of 
incorporating splicing association analyses. We use in vitro assays to validate the functional 
significance of splice-QTL associations for CHMP4C, and evaluate a gene knockout screen 
in HGSOC 22 to establish the functional essentiality for three of the novel spTWAS genes 
we identified: HAUS6, KANSL1 and PRC1.
RESULTS
Genetic control of gene expression after tumorigenesis
We first investigated the genetic control of gene expression in EOC precursor tissues and 
HGSOCs. We assayed genotype, gene expression, and quantified splicing data for 115 
primary normal ovarian surface epithelial cells (OSECs), 70 primary normal fallopian tube 
epithelial cells (FTSECs), and 394 primary HGSOCs profiled by The Cancer Genome Atlas 
(TCGA). FTSECs are a likely precursor cell type for the majority of HGSOCs 23–27 while 
OSECs are also a postulated cellular origin for the disease 28–33. We quantified the SNP-
heritability (h2g) and genetic correlation (rg) of gene expression and splicing between pairs 
of tissues (see Methods). For a given tissue, cis-h2g is defined as the fraction of phenotypic 
variance explained by SNPs within 500 kb of the gene boundary. For a pair of tissues, cis-rg 
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is defined as the correlation of causal genetic effects on expression across all SNPs within 
500 kb of the gene boundary. The average cis-h2g was significant in all tissues with an 
average of 0.026 for overall expression and 0.021 for splice variation, similar to previous 
observations across different tissues (Supplementary Table 1). There was a higher mean cis-
rg between FTSECs and HGSOCs (rg = 0.071, standard error [s.e.] = 0.031; Table 1) than 
between OSECs and HGSOCs (rg = −0.022, s.e. = 0.029) consistent with the hypothesis that 
FTSECs are the more likely precursor cell type for HGSOC. We observed a similar, albeit 
non-significant, trend for heritable splicing events, with a genetic correlation of 0.024 (s.e. = 
0.016) between HGSOCs and FTSECs, and −0.018 (s.e. = 0.013) between OSECs and 
HGSOC. There was a greater genetic correlation for both overall gene expression and 
splicing events between OSECs and FTSECs (rg = 0.359, s.e. = 0.046 for overall expression; 
rg = 0.302, s.e. = 0.023 for splicing) indicating that genetic control of gene expression is 
altered during tumorigenesis. Lastly, we evaluated rg between four molecular subtypes of 
HGSOCs characterized by gene expression signatures by TCGA 34 but observed no 
significant divergence from 1.0 and few individually significant genes (Supplementary Table 
2, 3). We therefore treated all HGSOCs as a single group for subsequent analyses.
Cross-cohort validation of TWAS models
We investigated the utility of the expression data assayed in OSECs, FTSECs and HGSOC 
and other hormonally-regulated cancers (breast and prostate cancers) in building prediction 
models for TWAS (Figure 1). In addition to OSEC, FTSEC and HGSOC data, we included 
RNA-seq data from 1,027 primary breast tumors and 84 matched normal precursor tissues, 
and 483 primary prostate cancers from TCGA 2,9,35. For TCGA cohorts, we also used exon 
junction events as a measure of alternative splicing to identify predictors that may not be 
observed through total expression (see Methods). We defined a “panel” as a tissue-state-
phenotype triplet (e.g. prostate-tumor-splicing) and performed normalization, correction, and 
model building within each panel separately so as not to induce confounding due to cross-
panel differences. A strength of the TWAS approach is that it is immune to reverse-causal 
effects of disease on gene expression (independent of genetics), and we show both 
theoretically and by simulation that this holds for case-only study design (Supplementary 
Note, Supplementary Figure 1). Each panel underwent stringent quality control and included 
as covariates genetic and gene expression/splicing principal components, local somatic 
structural variation, and relevant clinical factors (Supplementary Note, Supplementary Table 
4). Accounting for local structural variants significantly increased gene expression 
heritability for ovarian and breast tumors (Supplementary Figure 2), but tumor/pathology 
features such as purity, grade/stage, and hormone receptor status did not show substantial 
genetic heterogeneity except in the case of ovarian tumor expression from BRCA1/2 somatic 
mutation carriers (Supplementary Note, Supplementary Figure 2, Supplementary Table 3, 5).
A total of 13,762 significantly heritable genes and 53,579 significantly cis-heritable exon 
junction events were identified across all cohorts (cis-h2g P < 0.01, for detailed evaluation of 
cis locus and heritability parameters see Supplementary Note, Supplementary Table 6, 
Supplementary Figure 3, 4). We then trained multiple penalized predictive models using all 
SNPs in a locus and evaluated predictive accuracy by five-fold cross-validation against the 
actual measured expression (see Methods). Mean cross-validated predictor R2 was 0.066 
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(s.e. 4 × 10−4) and highly significant (median predictor cross-validation P = 4.6 × 10−4), 
consistent with previous findings that low average heritability of gene expression can be 
compensated for by sample size sufficient to produce reliable genetic predictors 
(Supplementary Table 7). We then leveraged the multiple independent cohorts analyzed here 
to assess replication rates for our predictive models with out-of-sample gene expression 
(Supplementary Note, Supplementary Table 8, 9). Both out-of-sample correlation and model 
significance were high across all cohorts and comparable to previous multi-tissue studies 36. 
Interestingly, predictive models built in tumors had the highest out-of-sample accuracy in the 
breast and prostate normal panels, consistent with tumor expression capturing genetic effects 
that are present in normal tissues. Predicting into the normal FTSEC and OSEC samples 
generally yielded the lowest replication (Supplementary Table 8, 9), likely due to the small 
size and heterogeneity of these cohorts (notably, predictors constructed in the normal 
FTSEC and OSEC samples still achieved high out-of-sample accuracy). Similar trends were 
observed when predicting into healthy samples from the Genotype Tissue Expression 
(GTEx) cohort (Supplementary Note, Supplementary Table 10, 11; Supplementary Figure 5 
for complete details of our validation procedure).
TWAS for EOC identifies candidate susceptibility genes
We performed a transcriptome-wide association study (TWAS) using the GWAS data from 
13,037 HGSOC cases and 40,941 controls estimated by the Ovarian Cancer Association 
Consortium (OCAC) 7 and our trained gene expression / splicing models (Figure 1). The 
genetically predicted expression of 32 gene-level models (18 unique genes) and 74 junction-
level models (17 unique genes) were significantly associated with risk after Bonferroni 
correction for 66,764 total tests (Supplementary Figure 6). TWASs may identify co-
incidental genetic associations due to partial tagging between the expression and disease 
causing variants, and so we performed additional conditioning and colocalization analyses 
on a locus-by-locus basis (see Methods).
We validated the expression models for each of the significant TWAS associations by 
predicting into the independent cohorts from other tissues/states (Supplementary Table 12–
14). 82/106 associated models were significantly correlated with expression/splicing 
measured in at least one independent cohort (after Bonferroni correction for 388 model-by-
cohort pairs tested, with 92/106 nominally significant after Bonferroni correction for 4 
cohorts tested). Mean replication R2 was 0.11 for overall expression and 0.10 for splicing 
and we observed no significant differences between the target datasets. 16/32 gene-level 
models were significantly correlated with gene expression (after Bonferroni correction) in 
the matching tissue in healthy GTEx samples and mean replication R2 was 0.12, 
demonstrating little average loss in predictive accuracy in healthy independent samples 
relative to independent TCGA samples (Supplementary Table 15). Overall we found that 
more heritable and better cross-validating genes were more likely to show up as significant 
TWAS associations (Supplementary Note, Supplementary Table 16, Supplementary Figure 
7–11).
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Novel genes implicated through TWAS
We first characterized gene-level events across the six tissue types, identifying 32 TWAS 
associations for 18 unique genes after Bonferroni correction (Table 2, Supplementary Table 
17, Supplementary Figure 6). A single association was detected in FTSECs: the non-coding 
RNA TIPARP-AS1 at 3q25.31 (TWAS P = 2.2 × 10−25). Seven genes were associated with 
risk in HGSOCs; CHMP4C 6 at 8q21.13, and six genes located within an inversion at 
chromosome 17q21.31 37. ARL17A was a notable example where ovarian-specific eQTLs 
explained the local GWAS signal, but significant eQTLs observed in breast and prostate 
were independent (Figure 2, Supplementary Figure 12, 13, Supplementary Table 18). After 
conditioning on the ARL17A ovarian tumor model (see Methods), the most significant 
conditional GWAS association in this locus was P = 0.002, whereas after conditioning on the 
ARL17A breast tumor model, the most significant conditional GWAS association was P 
=1.2 × 10−05, further supporting this as an ovary-specific association. ARL17A has not been 
previously implicated in ovarian cancer, although KANSL1-ARL17A gene fusions have 
been implicated in pancreatic cancer 38. Additionally, RCCD1 at 15q26, which had 
previously been implicated in a meta-analysis of breast and ovarian cancer 9 was here 
transcriptome-wide significant (TWAS P = 1.5 × 10−7 in prostate tumor). A follow-up 
colocalization analysis showed that 21/32 TWAS associations exhibited strong evidence of a 
single shared causal variant (PP4 > 0.8) and only 4/32 had evidence of joint causal variants 
(PP3 > 0.2). The number of significant associations was strongly correlated with the number 
of tested genes (R2 = 0.86) suggesting that these findings are driven by the size and the 
quality of the expression reference dataset, rather than tissue specificity (Supplementary 
Figure 14).
We replicated 10/18 unique genes using independent prediction models from the GTEx 
study after Bonferroni correction (Supplementary Table 19). Only two were significant using 
GTEx ovary models - the paralogs LRRC37A and LRRC37A2, which were significant in 
nearly all tissues except for testis and normal prostate tissues (Supplementary Table 15). A 
TWAS analysis of all 84,064 available GTEx models identified two additional 
transcriptome-wide significant loci: MLLT10 at 10p12.31 which was significant in leg and 
spleen; and DNALI1 at 1p34 which was significant in 9 tissues (but not in breast, prostate or 
ovary). The DNALI1 locus was previously reported as genome-wide significant in serous 
EOC where the RSPO1 gene was proposed as a putative target gene, but no eQTL 
association was detected 11. Conditioning on the predicted expression of DNALI1 accounted 
for all the genome-wide significant signal, consistent with these genes being potential 
mediators of the association (Supplementary Figure 15). In breast tissue, where models were 
trained in TCGA tumor and normal tissues and GTEx healthy tissues, genes that were 
predictable in multiple cohorts produced highly concordant TWAS test statistics, 
underscoring the consistency of these models between tumor/normal and case/control 
expression (Supplementary Figure 5).
Novel transcripts implicated through junction spTWAS
Next, we performed a spTWAS across all significantly heritable exon junction events, 
identifying 74 splice-TWAS associations with EOC risk in 18 unique genes (after 
Bonferroni correction; Table 2, Supplementary Table 20). This included 7 genes that did not 
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have a significant gene-level TWAS association in the TWAS analysis of overall expression. 
Colocalization analysis 39 showed that 58/74 associations were consistent with a shared 
causal variant (posterior on shared > 0.8) and 70/74 were inconsistent with a single distinct 
causal variant (posterior on distinct < 0.2). Three loci contained only a single significantly 
associated gene and we investigated these loci in detail.
First, we identified a splice-TWAS association for PRC1 (in breast tumors) which fully 
explains the GWAS signal at the 15q26.1 locus (TWAS P = 8.9 × 10−8, PP4 = 1.0), which is 
associated with both breast and ovarian cancer risk 9 (Figure 3). This spTWAS model 
replicated significantly in ovarian tumor tissue (P = 8.6 × 10−4; Supplementary Table 13). 
Notably, we found no significant eQTLs for overall expression of PRC1, highlighting a 
genetic effect on splicing that is independent of total expression. We separately identified a 
significant TWAS association for the nearby RCCD1 gene in prostate tumors which is 
modestly correlated with PRC1 (Supplementary Figure 9) and was previously implicated as 
a candidate breast/ovarian cancer susceptibility gene 9. Second, we identified multiple 
spTWAS associations for CHMP4C (in all tumor panels) which fully explained the 8q21 
locus. CHMP4C harbors a missense risk variant and was previously implicated by eQTL 
analysis 6. Here, the lead spQTL (rs74758321; GWAS P = 1.1 × 10−10) is within 300 bp of 
the splice junction and in perfect linkage disequilibrium with the top GWAS SNP at this 
locus, further implicating splicing as the potential causal mechanism (see additional 
validation below). Third, we identified a splice-TWAS association for HAUS6 (in prostate 
tumors) at the 9p22.1 locus (TWAS P = 2.8 × 10−7, PP4 = 0.7, PP3 = 0.01) which was not 
genome-wide significant (GWAS P = 5.9 × 10−6). Although a conditional analysis fully 
accounted for the local GWAS signal (Supplementary Figure 16), cross-validation accuracy 
of the predictive model was nominally significant (P = 2.8 × 10−3) and the model did not 
replicate in other tissues (Supplementary Table 13), necessitating further replication to 
confirm this locus.
The majority of associations (51/74) were at the 17q21.31 locus within an inversion 
polymorphism spanning ~900 kb. This region contains hundreds of variants in high linkage 
disequilibrium that all represent putative causal alleles and are involved in genetic co-
regulation of 9 genes, with evidence of multiple clusters of independent associations 
(Supplementary Figure 11). We observed a complex co-regulation of >3 unique genes at one 
other locus - 19p13.11 - with evidence of multiple independent associations. We performed 
stepwise conditional analysis of all significant TWAS/spTWAS associations in the locus to 
identify the minimal set of genes that jointly explained the most genome-wide significant 
signal. The final model contained two splicing events for the BABAM1 gene 
(chr19:17378336–17379565 in ovarian tumors and chr19:17378336–17379603 in prostate 
tumors, correlated with R2 = 0.59), reducing the lead GWAS SNP from P = 7.8 × 10−25 to P 
= 8.2 × 10−6 (Supplementary Figure 11, 17). The 19p13.11 risk locus is also associated with 
triple-negative breast cancer 2 and BABAM1, a known BRCA1-interacting protein, is 
therefore a compelling target gene. Our previous gene-level functional studies failed to find 
strong functional evidence of a role for BABAM1 in ovarian and breast tumorigenesis, but 
instead implicated the neighboring genes ABHD8 and ANKLE1 2. These new analyses 
suggest that characterizing the functional significance of BABAM1 splice variants is 
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warranted. Further studies will be needed to understand these apparently contradictory 
results which suggest either multiple causal variants or complex local haplotype structure.
GWAS variance and pleiotropy explained by TWAS associations
Overall, the GWAS contained 13 contiguous genome-wide significant regions, of which 6 
were within 500 kb of a TWAS or splice-TWAS association (Supplementary Table 21). 
These 6 regions implicated a total of 106 associated features out of a 1,134 tested, 
demonstrating a substantial number of heritable gene/tissue combinations that have also 
been ruled out as likely cis targets. All gene expression and splicing models, without 
thresholding, explained 31% (s.e. 11%; P = 3.5 × 10−3) of EOC SNP-heritability (estimated 
by a modified LD-score regression, see Methods). This estimate includes any tagged genetic 
effects that alter expression and risk independently, and thus should be interpreted as an 
upper bound.
We further tested the 106 transcriptome-wide significant features (74 splice events and 32 
genes) for pleiotropic associations with breast cancer risk from a recent breast cancer risk 
GWAS 40. 70 out of 106 features showed evidence of significant TWAS association (P < 
0.05/106), demonstrating extensive pleiotropy between breast and ovarian cancer at these 
loci that appears to operate through the same genes (Supplementary Table 22). No 
significant differences were observed in the rate of pleiotropic association using breast, 
prostate, or ovarian models (Supplementary Table 23). Of the 70 pleiotropic associations, 
four were genome-wide significant (P < 5 × 10−8) for breast cancer: gene-level association 
with RCCD1, and exon-level associations with PRC1, LRRC37A, and KANSL1. These 
results highlight two robust genome-wide significant loci associated with breast and ovarian 
cancer that also exhibit effects on expression of the same genes. We repeated the same 
analysis for a recent GWAS for prostate cancer 41 but did not identify any features 
significant after Bonferroni correction, suggesting that the extensive expression-based 
pleiotropy we observe between breast and ovarian cancer is not expected by chance.
Functional assays support the CHMP4C splicing association
As described above, we identified four spTWAS associations in the CHMP4C gene, the most 
significant of which was rs74758321, which is in perfect linkage disequilibrium with the top 
GWAS risk SNPs for ovarian cancer identified in this region. In silico and in vitro functional 
analyses were performed to established if this is a likely causal SNP at this locus. SNP 
rs74758321 is most significantly associated with the chr8:82665476:82667605 junction in 
ovarian, breast, and prostate tumors with similar effect-sizes across all phenotypes 
(Supplementary Table 24). In a joint regression testing of the association between the SNP 
and all four splice junctions, this junction was the most significant feature in all tumor 
cohorts, but was non-significant in the normal tissues, though a significant joint association 
was observed for other junctions as well (Supplementary Table 25). This was also the only 
variant identified that fell within the consensus splice site sequence (within 300 bp of a 
junction). We therefore evaluated the effects of different alleles of rs74758321 on splicing in 
an in vitro splicing reporter assay performed in FUOV1 ovarian cancer cells. We observed 
exon inclusion (7.6+/−1.6%) more frequently in cells transfected with the ‘A’ allele 
compared to the ‘G’ allele (P = 0.0024, two tailed paired Student’s T-test) (Figure 4).
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Importantly, we did not observe functional evidence supporting transcriptional regulatory 
activity or the previously implicated missense variant. Enhancer scanning assays performed 
to evaluate allele-specific enhancer activity of ~2 kb genomic tiles containing nine credible 
(1:100) causal variants identified in GWAS, including rs74758321, at this locus failed to 
detect any differential regulatory activity (Supplementary Note, Supplementary Figure 18). 
In addition, we performed a CHMP4C protein stability analysis to determine the effect of 
the missense variant SNP rs35094336 (Ala232Thr). No difference was observed in protein 
expression in transiently transfected ovarian (IOSE4CMYC) or 293FT human embryonic 
kidney cells. Also, no change in the stability of CHMP4C containing either the rs35094336 
‘A’ or ‘G’ allele was detected after cycloheximide treatment (not shown).
Genes showing evidence of essentiality in a knockout screen
We explored the functional role of the 25 candidate susceptibility genes identified from our 
TWAS and spTWAS analyses using publicly available data from a gene essentiality screen 
22
. We utilized gene knockout data for 24 genes in 13 HGSOC cell lines (Figure 5). Three 
genes showed evidence of essentiality (CERES Score < −0.5) - KAT8 regulatory NSL 
complex subunit 1 (KANSL1, mean CERES score = −0.53, s.d. = 0.15), HAUS Augmin 
Like Complex Subunit 6 (HAUS6, mean CERES score = −0.84 s.d. 0.07), and protein 
regulator of cytokinesis 1 (PRC1, mean CERES score = −1.13, s.d. = 0.14). PRC1 shows 
similar levels of essentiality as MYC, a key oncogenic transcription factor in many tumor 
types, including ovarian cancer 42. All three genes were identified only through the splice-
TWAS and not previously reported. Indeed, the mean CERES score across significant splice-
TWAS genes (−0.21 s.e. 0.03) was significantly lower (i.e. more essential) than that of genes 
not associated through splicing (−0.01 s.e. 0.02; P = 4.8 × 10−6 for difference by Wilcoxon 
rank sum test). This significant difference suggests that risk variants affecting splicing, and 
thus protein structure, may be more likely to target essential genes in ovarian cancer cells 
than risk variants that apparently only affect transcription (i.e. protein abundance). As the 
CERES functional screens model complete gene knockouts, further functional assays of 
specific isoforms and allelic series will be required to validate this hypothesis.
DISCUSSION
In this study we integrated tissue specific gene expression and genotyping data with the 
largest GWAS dataset available for HGSOC 7 to identify 25 candidate susceptibility genes, 
one of which was experimentally validated and three which showed promising functional 
evidence of essentiality. The spTWAS analysis identified 7 genes that were not implicated 
by the gene-level TWAS, nearly doubling the number of candidate susceptibility genes we 
identified. This included PRC1 (at 15q26.1) which explained all of the GWAS signal while 
exhibiting no eQTL association and was not previously identified in a locus-specific eQTL 
analysis. Notably, PRC1 showed similar levels of essentiality as MYC (a known essential 
gene and likely GWAS target gene in HGSOC 13) strongly indicating PRC1 plays a 
functional role in the development of ovarian tumors. In breast, ovarian and prostate tumors 
we identified an spTWAS association for CHMP4C, at chromosome 8q21.13. In an in vitro 
splicing assay, the two alleles of rs74758321 were associated with significantly different 
rates of exon 3 inclusion. We performed comprehensive testing for allele-specific activity for 
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all candidate causal variants in the region, using a set of in vitro assays that are commonly 
used to evaluate allele-specific activity of risk SNPs, including enhancer scanning, 
electrophoretic mobility shift assays and protein stability assays 2,40,43–45. Beyond the 
validated role for rs74758321 in splicing there was no evidence to support a functional role 
for any of the other candidate causal variants at this locus, indicating rs74758321 is the most 
likely ‘causal’ variant at this risk locus. Taken together, these findings indicate that 
alternative splicing should be considered more broadly in post-GWAS functional analyses. 
CHMP4C expression has been implicated in several cancers and has been proposed as a 
diagnostic tumor marker and therapeutic target for ovarian cancer 46,47. We observed a 
striking overlap between significant TWAS genes in GWAS for HGSOC and a recent GWAS 
of breast cancer 40, including genome-wide significant associations with PRC1 and 
KANSL1. These findings merit further studies based on TWAS methodologies to identify 
pleiotropy and common cancer susceptibility genes for these cancers.
It remains likely that our TWAS analysis missed a unquantifiable proportion of true 
associations, while some associations may represent false positive findings due to chance co-
regulation 21. This is emphasized by a recent parallel publication from Lu et al. 48 reporting 
a TWAS for ovarian cancer using total expression models constructed in the GTEx cohort. 
The use of distinct transcriptomic data in our study and our focus on splicing variation likely 
contributes to the differences in the candidate ovarian cancer susceptibility genes identified 
in each study. In particular, the one novel locus identified by Lu et al., FZD4 at 11q14.2 and 
a plausible candidate because of its role as a member of the frizzled gene family associated 
with Wnt signaling, was not heritable in any of the tissues we investigated (h2g < 0.006 in 
any tissue). We note that selecting the appropriate tissue/cell type for TWAS is critical in 
avoiding false positives in causal gene identification from TWAS and remains an active 
research area for TWAS analyses; see ref. 21 for a broader discussion of tissue choice in 
causal gene identification following TWAS or ref. 7 for a specific discussion of tissue of 
origin for different histotypes of epithelial ovarian cancer. Future studies to improve the 
power of TWAS analysis in ovarian cancer will need to establish substantially larger gene 
expression and genotyped datasets for normal precursor tissues, for HGSOC and for other 
EOC histotypes that were not evaluated in the current study.
In summary, we have performed a TWAS based on the integration of GWAS data for 
HGSOC and gene expression data for both normal and tumor tissues associated with 
HGSOC pathogenesis, to identify candidate susceptibility genes associated with inherited 
HGSOC risk. Most importantly, this study established spTWAS associations as a major 
component of HGSOC heritability, a principle that also likely applies to many other 
phenotypes.
ONLINE METHODS
Data processing and QC
Genotypes.—Germline DNA from normal OSEC and FTSEC samples were genotyped 
using the Oncoarray platform 7. For TCGA data, SNP genotype calls using Birdsuite were 
downloaded from the TCGA legacy archive and imputed using the EAGLE pipeline 
provided by the Michigan imputation server. The following genotype QC was performed 
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across all studies: SNPs were retained if they had imputation INFO>0.9; locus missingness 
<5%; Hardy-Weinberg equilibrium two-tailed P-value > 5 × 10−6; and minor allele 
frequency > 1% (thresholds based on GTEx Consortium recommendations). Individuals 
were excluded if they had more than 5% missing sites. Two genotype principal components 
were computed to account for ancestry and included as covariates in all subsequent analyses.
Gene/exon expression in HGSOC precursor tissues.—OSECs and FTSECs were 
harvested from histologically normal ovaries and fallopian tubes removed from women 
diagnosed with ovarian, uterine or cervical cancer. Short-term cultures were established 
49,50
. OSECs were harvested using a cytobrush and cultured in NOSE-CM media containing 
15% fetal bovine serum (FBS, Hyclone), 34 μg ml−1 bovine pituitary extract, 10 ng ml−1 
epidermal growth factor (Life Technologies), 5 μg ml−1 insulin and 500 ng ml−1 
hydrocortisone (Sigma-Aldrich). Fallopian epithelia were dissociated from stromal tissues 
by Pronase/DNase I digestion (Roche and Sigma-Aldrich, respectively) for 48–72 hours at 
4°C. Purified epithelia were cultured on collagen I (Sigma-Aldrich) using DMEM/F12 base 
media supplemented with 2% Ultroser G (Pall Corporation). At ~80% confluency, cells were 
lysed using the QIAzol reagent and RNA extracted using the RNeasy Mini kit (both 
QIAgen). RNA sequencing was performed by the University of Southern California 
Epigenome Core Facility using 50 bp single end reads. All data processing was performed 
using ‘R’ and ‘Bioconductor’, and packages therein.
RNAseq data for 394 HGSOC samples was obtained from The Cancer Genome Atlas 
(TCGA) data portal as protected data (raw sequencing, fastq files) and downloaded via 
CGHub’s geneTorrent. Data were aligned to a reference genome (hg19) using STAR. 
Quality control of aligned samples was performed using RSeQC. GC bias and batch effect 
corrections were performed using EDASeq and ‘sva’. To adjust for batch effects we used an 
empirical Bayes framework (comBat), available in ‘sva’.
Gene/exon expression in non-ovarian TCGA samples.—Normalized gene and exon 
level events were downloaded from the TCGA FireCloud. Exon usage was previously 
quantified using MapSplice. Finally, all expression/exon measurements were quantile 
normalized. As with the ovarian data, all expression/exon measurements were quantile 
normalized and three expression principal components were computed and used as 
covariates in all subsequent analyses.
Gene expression in GTEx samples.—Processed and normalized expression and 
genotypes were downloaded from dbGAP and the GTEx Portal as described in 51. For each 
tissue the following covariates were included in all analyses: three genetic principal 
components, sex, platform, and 14–35 expression factors 52 as selected by the main GTEx 
analysis.
Clinical factors for TCGA samples.—We extracted all relevant clinical factors 
available for TCGA samples for use as covariates and to evaluate expression heterogeneity 
(Supplementary Table 4, 5). We quantified BRCA1/2 somatic mutation carriers using 
MutSigCV2 calls from tumor whole-exome sequencing made available by TCGA. We 
quantified somatic structural variants using BirdSuite CNV calls from tumor/normal 
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genotype array data made available by TCGA. Tumor purity was systematically estimated 
across the TCGA cohorts by Aran et al. 53.
Heritability and genetic correlation
To evaluate tumor subtype heterogeneity we quantified the genetic correlation of gene 
expression between subtypes. For each panel and factor we divided the samples into two 
groups either as carriers/non-carriers for dichotomous factors such as somatic BRCA1/2 
mutation, or as low/high for quantitative factors such as age. Mean heritability and genetic 
correlation were estimated using Haseman-Elston regression 54 as implemented in GCTA 55. 
All SNPs within 500 kb of the gene boundary were used to define the cis locus and construct 
the corresponding kinship matrix. Standard errors for genetic correlation across all genes 
were estimated as in 56.
Construction and validation of gene prediction models
TWAS predictors were computed using the FUSION software (see Web Resources). Briefly, 
for each gene or exon junction, SNPs from +/−500 kb of the feature boundary were extracted 
and used to estimated cis-SNP-heritability 55. Clinical features and gene expression principal 
components were always included as covariates to account for trans variation (see 
Supplementary Note for detailed analyses). Features that had nominally significant cis-SNP-
heritability (likelihood ratio test P<0.01) were retained for model building and TWAS. We 
elected to use a heritability-based cutoff rather than specify a cutoff on the cross-validation 
R2 because the former uses all available data, however we report both statistics for all 
associations. Notably, for the 106 TWAS-significant models, 105/106 has nominal cross-
validation P<0.05 and 85/106 had Bonferroni significant cross-validation P<0.05/106. The 
genotypes were used to train TWAS predictive models using BLUP, elastic net, and LASSO 
algorithms.
Five-fold cross-validation was performed for each reference panel and gene/splicing model. 
Gene expression for each fold of the data was hidden in turn; the full prediction model was 
then trained on the remaining expression and genetic data; and the trained model was then 
predicted into the held-out fold samples. This procedure was repeated across all folds to 
compute the overall cross-validated prediction, an adjusted R2 (and corresponding two-tailed 
P-value) was then computed between the cross-validated prediction and the measured 
expression by ordinary least squares. The lasso and elastic net models require a penalty 
parameter that is itself fit by leave-one-out cross-validation and this was performed within 
each fold (i.e. double cross-validation where the testing data is hidden from all parameter 
tuning). Across all tissues and features, the top eQTL was the best predictor only 26% of the 
time. Surprisingly, the BLUP predictor - which has the weakest penalization in favor of 
sparsity - was the most common best predictor (best 33% of the time), suggesting a greater 
degree of effect heterogeneity in this data than studies of normals where cis-expression 
effects are typically sparse 57.
For models trained in GTEx (v6), TWAS expression weights were previously computed as 
described in 16, and downloaded from the FUSION website.
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We investigated the concordance in heritability and R2 estimates between the TCGA tumors 
and the corresponding healthy GTEx tissues. For each pair of TCGA/GTEx tissues we 
measured Pearson correlation (and significance) between the estimated cis-heritability 
across all evaluated genes. We note that the GTEx heritability estimates have greater 
estimation error than signal (mean cis-h2g estimate 0.042, mean s.e. estimate 0.045) which is 
expected to greatly deflate this estimate. We therefore additionally estimated the relationship 
between the two estimates using regression of GTEx estimate on TCGA estimate 
(Supplementary Table 11). We similarly evaluated the correlation between the TCGA in-
sample cross-validation R2 and the TCGA-into-GTEx prediction R2.
Correlation of predictive models between the TCGA panels was estimated in the 1000 
Genomes Project European reference samples. First, each model was predicted into the 
reference samples. Second, for each gene that was modelled in multiple panels and each pair 
of panels, the correlation between predicted values from panel 1 and panel 2 was computed. 
The mean correlation across all pairs of panels and shared genes is reported in 
(Supplementary Table S12).
TWAS analysis
GWAS data.—GWAS data from the Ovarian Cancer Association Consortium as described 
in 7 were downloaded and aligned to hg19 HapMap3 SNPs (excluding A/T or C/G SNPs due 
to strand ambiguity). These SNPs are consistently imputed with high accuracy across diverse 
genotyping platforms and were used to compute all TWAS weights.
TWAS tests.—The FUSION software was used to perform TWAS tests across all 
predictive models 17. Models were considered “transcriptome-wide significant” if they 
passed Bonferroni correction for all genes and exon events tested.
Summary-based conditional analyses between TWAS and GWAS associations were 
performed using FUSION 58. For a given significant TWAS association, the gene/exon 
expression was predicted into the 1000 Genomes EUR samples to estimate the LD between 
the predicted model and each SNP in the locus. Each GWAS SNP was then conditioned on 
the predicted model using the LD estimate to quantify the amount of residual association 
signal. Stepwise model selection was performed by including each TWAS-associated feature 
(from most significant to least) into the model until no feature remained conditionally 
significant.
Summary-based conditional analyses for individual SNPs were performed using GCTA-
COJO 58. Colocalization analyses were performed using the COLOC software 39 and the 
marginal eQTL/spQTL statistics for a given feature.
Conditional and colocalization analyses
First, we condition every GWAS association on the predicted value of each significant 
TWAS gene to assess how much association signal remains independent of the TWAS 
association (see Methods). We note that comparing GWAS and TWAS effect-sizes directly 
poses a challenge because the associations are on different scales: GWAS effect-sizes are on 
the allelic odds ratio scale, whereas TWAS effect-sizes are on the standardized expression 
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scale as there is no formal “allele” for the expression predictor. Instead, the conditional 
analysis serves to quantify whether the TWAS association can “explain” the GWAS 
association after accounting for correlation between the predictive model and GWAS risk 
SNPs. Residual GWAS signal, after conditioning, is an indicator that the TWAS association 
is partially tagging the causal variants, or that other independent causal variants are present 
at the locus (as with SNP-based conditioning).
Second, we perform a “colocalization” analysis using the COLOC software 39, which 
evaluates the posterior probability that the genetic association to the gene/exon is driven by a 
single shared causal variant with the GWAS risk association (termed “PP4” in the COLOC 
notation). This model does not consider colocalization between multiple causal variants, so 
high PP4 is a more stringent threshold to clear than the TWAS association and may miss true 
colocalization at loci with heterogeneous effects on expression and disease. COLOC 
additionally estimates the probability that the expression and GWAS are driven by two 
distinct causal variants (PP3), and we use low PP3 as a less stringent threshold for evidence 
of non-independent association signal (though it may still be confounded by multiple causal 
variants).
Functional analyses
CHMP4C spQTL analyses: We tested rs74758321 for association to CHMP4C junction 
usage in each of the TCGA cohorts (Supplementary Table 24, 25; Life Sciences Reporting 
Summary). To keep effect sizes as consistent as possible across the studies (and since these 
junctions were already shown to be highly heritable with all covariates), we did not 
incorporate any covariates and only performed simple rescaling of each junction count to 
mean 0, variance 1. We first tested each junction (in each tissue) in turn for association to the 
SNP by OLS regression (Supplementary Table 24). We then tested the joint effect of the 
SNP on junction usage by reversing the regression : SNP ~ junction1 + junction2 + 
junction3 + junction4 (Supplementary Table 25). While the individual effect-sizes from this 
multiple regression are difficult to interpret, the significance of each association is an 
indicator of which junction more strongly drives the genetic association.
For splicing assays, IOSE11 cells were grown in NOSE-CM 59 and FUOV1 ovarian cancer 
cells were grown in DMEM/F12 (Thermo Fisher Scientific) supplemented with 10% FBS 
(Sigma-Aldrich) and L-Glutamine (Lonza, Catalogue number:17–605E). A minigene 
construct was generated to include chr8:82667209–82668009, representing CHMP4C exon 
3 +/− ~350 bp (see Supplementary Note for primers used). IOSE11 DNA was used as a 
template for PCR, as this cell line is heterozygous for rs74758321. PCR products were 
cloned into the splicing reporter vector pZW1 60 to generate a pair of plasmids containing 
the two alleles of SNP rs74758321. The constructs were confirmed by double digestion and 
further verified by Sanger sequencing. Twelve-well FUOV1 ovarian cancer cells were 
transfected with 2 μg splicing reporter when cells are 80% confluency. Cells were harvested 
24 h post transfection and total RNA was subsequently extracted. cDNA was made from 5 
μg of total RNA by reverse transcription and one twentieth of cDNA was used as template to 
amplify both inclusion and skipping form of splicing reporter GFP transcript with or without 
CHMP4C exon 3 by PCR within 25 cycles using GFP-F and GFP-R (see Supplementary 
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Note). PCR products were subjected to 5% polyacrylamide gel electrophoresis, and the 
resulting gels were imaged. Expression of each band was quantified using ImageJ software 
(http://imagej.nih.gov/ij/) and the inclusion rate of the target exon was calculated.
Enhancer scanning assays -: We tested ~2 kb tiles containing all nine (rs137960856, 
rs11782652, rs74544416, rs78740005, rs78724141, rs111683632, rs74758321, rs76837345, 
rs35094336) credible (1:100; 10/26/2015 imputation) SNPs in this locus for regulatory 
enhancer activity using enhancer scanning 61 in IOSE4CMYC cells 62. Tiles were tested in 
both orientations. Primers are provided in Supplementary Table 27.
Protein stability assays -: SNP rs35094336 missense variant (Ala232Thr) was evaluated for 
CHMP4C protein stability. CHMP4C cDNA containing each allele were cloned into 
pCMV6-entry vector. iOSE4CMYC cells were stably transfected with FuGENE-HD and 
clones selected by G418 (500 μg/ml, Gibco). Stable clones were treated with cicloheximide 
(Sigma) for up to 48 h and protein levels were assessed. The missense variant (rs35094336) 
does not impact CHMP4C transcript stability.
Knockout screen data analyses -: Differential gene expression analyses were performed 
using the OSEC, FTSEC and HGSOC data sets described above. Processed CERES 
knockout data were downloaded 22 and data for the 13 HGSOC lines included in this study 
were used in our analyses.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Study schema.
Overview of the analytic workflow. CNV, copy number variation; FTSEC, fallopian tube 
secretory epithelial cell; OSEC, ovarian surface epithelial cell; PC, principal component; 
spTWAS, splice transcriptome-wide association study; TWAS, transcriptome-wide 
association study.
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Figure 2. Ovary-specific TWAS association for ARL17A.
The ARL17A gene is under strong genetic control in multiple tissues but only colocalizes 
with GWAS in ovarian tumors. Each panel shows Manhattan plot of SNP-phenotype 
association before (gray) and after (blue) conditioning on the TWAS predictor trained on 
ovarian tumor expression: a, GWAS associations, with signal fully explained after 
conditioning on the predictor (N = 53,978); b, ovarian tumor eQTLs (N = 201); c, breast 
tumor eQTL (N = 654); d, prostate tumor eQTL (N = 376). a and b show that associations 
are explained by the ovarian TWAS predictor, whereas c and d show that associations are 
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independent of the ovarian TWAS predictor. Two sided p-value was computed from the 
GWAS summary data (a) or by linear regression (b-d).
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Figure 3. Splice-TWAS association at PRC1 implicates novel target gene independent of genetic 
effects on total expression.
Panels a, b, d show Manhattan plot of SNP-phenotype association before (gray) and after 
(blue) conditioning on the top splice-QTL (a: GWAS, N = 53,978; b,c: breast tumor 
junction, N = 654; d,e: breast tumor expression, N = 654). Panels c, e show box and scatter 
plots of normalized junction (top) and overall (bottom) expression, stratified by lead GWAS 
SNP genotype. Two sided p-value was computed from the GWAS summary data (a) or by 
linear regression (b-e). c,e: thick line is median, box is the interquartile range (IQR), 
whiskers are quartiles plus 1.5 IQR.
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Figure 4. CHMP4C splicing is associated with EOC risk allele.
a. Schematic of the splicing assay, CHMP4C exon 3 with flanking intronic sequence was 
cloned into a splicing reporter vector. Plasmids were generated to harbor either the ‘G’ or 
‘A’ allele of the SNP. b. In FUOV1 ovarian cancer cells the ‘A’ allele is associated with 
higher rates of exon inclusion. PSI, percent spliced in. Data shown are mean with SD from 
N = 4 independent experiments, ** P =0.0024, two-tailed paired Student’s T-test.
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Figure 5. Functional analyses show evidence of essentiality for three TWAS/spTWAS genes.
a. Gene knockout experiments to determine gene essentiality for 13 HGSOC cell lines. 
CERES Score is a copy number corrected indicator of depletion of gene-targeting guide 
RNAs; the lower the CERES Score, the more essential the gene. MYC is a known essential 
gene and is included as a positive control. CERES Score thresholds corresponding to the 
median score for non-essential and essential genes are indicated with a blue dashed line at 0 
and red dashed line at −1, respectively. Genes with a CERES Score ≤ −0.5 (and therefore 
showing evidence of essentiality) are highlighted with purple boxes. b. Relative expression 
of each gene in OSECs (N = 120), FTSECs (N = 71) and HGSOCs (N = 394). ARL17B and 
TIPARP-AS1 were not evaluated in the CERES screen and were therefore excluded from the 
plots. Boxes in each plot represent the first and third quartiles, and whiskers extend to 1.5 * 
IQR.
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Table 1.
Genetic correlation of expression and splicing in ovarian tissues.
Genetic variance/covariance was estimated across all significantly heritable genes (in any panel) using HE-
regression, averaged, and transformed to genetic correlation (rg). Standard error shown in parentheses. Sample 
size: 201 tumor HGSOC, 70 normal FTSEC, 115 normal OSEC.
Expression Overall rg (se)
Tumor HGSOC Normal OSEC −0.022 (0.029)
Tumor HGSOC Normal FTSEC 0.071 (0.031)
Normal OSEC Normal FTSEC 0.359 (0.046)
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Table 2.
TWAS analyses in ovarian cancer.
FTSEC, fallopian tube secretory epithelial cell; OSEC, ovarian surface epithelial cell; HGSOC, high-grade 
serous ovarian cancer.
Site Type Samples Tested genes Tested splice variants Significant genes Significant splice variants Significant 
splice 
variant 
genes
Breast Normal tissue 84 1984 5391 3 9 3
Breast Tumor tissue 654 4465 21568 7 23 9
Ovary Normal FTSEC 70 541 - 2 - -
Ovary Normal OSEC 115 607 - 0 - -
Ovary Tumor tissue (HGSOC) 201 1744 8759 7 18 8
Prostate Tumor tissue 376 4414 17857 13 24 10
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